Grootveld Martin, McDermott Michael F
Department of Diabetes and Metabolic Medicine, Queen Mary, University of London, Mile End Road, London E1 1BB, UK.
Curr Opin Investig Drugs. 2003 May;4(5):598-602.
Bristol-Myers Squibb Pharma Co is developing the tumor necrosis factor-alpha (TNF alpha) converting enzyme inhibitor BMS-561392 (DPC-333) for the potential treatment of diseases characterized by overproduction of TNF alpha, such as rheumatoid arthritis (RA). A phase IIa trial in RA patients had commenced by April 2001, and by October 2002, BMS-561392 was also under investigation for the potential treatment of inflammatory bowel disease.
百时美施贵宝制药公司正在研发肿瘤坏死因子-α（TNFα）转化酶抑制剂BMS-561392（DPC-333），用于潜在治疗以TNFα过度产生为特征的疾病，如类风湿性关节炎（RA）。到2001年4月，针对RA患者的IIa期试验已经开始，到2002年10月，BMS-561392也正在接受用于潜在治疗炎症性肠病的研究。
